New implant aims to ease stubborn back pain

NCT ID NCT07565545

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test a titanium implant designed to fuse the sacroiliac joint in people with chronic lower back pain that hasn't responded to non-surgical treatments. About 120 adults with sacroiliac joint dysfunction will receive the implant and be followed for safety and pain relief. The main goal is to see if the implant reduces pain by at least 2 points on a 10-point scale without causing serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

iFuse INTRA Ti Implant System (titanium implant for sacroiliac joint fusion)

What this could lead to

If successful, this could provide a safe and effective surgical option for people with chronic sacroiliac joint pain that hasn't improved with other treatments.

What could go wrong

This is a single-arm study without a comparison group, so results may be less conclusive. As with any surgery, there are risks of infection, device-related problems, or no pain relief.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SACROILIAC JOINT DYSFUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthritis, sacroiliac

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••